Breast Cancer Clinical Trial

An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg

Summary

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole

View Full Description

Full Description

To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products (PCNA, cyclin-D1, ER alpha, PR, pS2, 450 aromatase, bcl-2, bax, caspase-3, and VEGFR) that may be useful as predictors or indicators of response to letrozole

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

evidence of hyperplasia with/without atypia upon random periareolar fine needle aspiration of breast
on hormone replacement therapy
postmenopausal
increased risk of developing breast cancer based on personal or family history
never have taken aromatase inhibitors or selective estrogen receptor modulators in last six months
women who have a high risk of breast cancer
older than 18 years

Exclusion Criteria:

no anticoagulants
no marked breast tenderness
not pregnant or within twelve months of breast feeding/childbirth

Study is for people with:

Breast Cancer

Estimated Enrollment:

40

Study ID:

NCT00291109

Recruitment Status:

Completed

Sponsor:

University of Kansas

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Kansas Medical Center
Kansas City Kansas, 66160, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

40

Study ID:

NCT00291109

Recruitment Status:

Completed

Sponsor:


University of Kansas

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.